Reduction of Phosphorylated Tau in Alzheimer’s Disease Induced Pluripotent Stem Cell-Derived Neuro-Spheroids by Rho-Associated Coiled-Coil Kinase Inhibitor Fasudil
Restricted accessResearch articleFirst published online December 6, 2023
Reduction of Phosphorylated Tau in Alzheimer’s Disease Induced Pluripotent Stem Cell-Derived Neuro-Spheroids by Rho-Associated Coiled-Coil Kinase Inhibitor Fasudil
Alzheimer’s disease (AD) is the most predominant form of dementia. Rho-associated coiled coil kinase (ROCK) inhibitor, fasudil, is one of the candidate drugs against the AD progression.
Objective:
We aimed to investigate possible changes of AD associated markers in three-dimensional neuro-spheroids (3D neuro-spheroids) generated from induced pluripotent stem cells derived from AD patients or healthy control subjects (HC) and to determine the impact of pharmacological intervention with the ROCK inhibitor fasudil.
Methods:
We treated 3D neuro-spheroids with fasudil and tested the possible effect on AD markers by ELISA, transcriptomic and proteomic analyses.
Results:
Transcriptomic analysis revealed a reduction in the expression of AKT serine/threonine-protein kinase 1 (AKT1) in AD neuro-spheroids, compared to HC. This decrease was reverted in the presence of fasudil. Proteomic analysis showed up- and down-regulation of proteins related to AKT pathway in fasudil-treated neuro-spheroids. We found an evident increase of phosphorylated tau at four different residues (pTau181, 202, 231, and 396) in AD compared to HC-derived neuro-spheroids. This was accompanied by a decrease of secreted clusterin (clu) and an increase of intracellular clu levels in AD patient-derived neuro-spheroids. Increases of phosphorylated tau in AD patient-derived neuro-spheroids were suppressed in the presence of fasudil.
Conclusions:
Fasudil modulates clu protein levels and enhances AKT1 that results in the suppression of AD associated tau phosphorylation.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
2.
MetaxasA, KempfSJ (2016) Neurofibrillary tangles in Alzheimer’s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res11, 1579–1581.
HollingworthP, HaroldD, SimsR, GerrishA, LambertJC, CarrasquilloMM, AbrahamR, HamshereML, PahwaJS, MoskvinaV,
et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet43, 429–435.
van DyckCH, SwansonCJ, AisenP, BatemanRJ, ChenC, GeeM, KanekiyoM, LiD, ReydermanL, CohenS, FroelichL, KatayamaS, SabbaghM, VellasB, WatsonD, DhaddaS, IrizarryM, KramerLD, IwatsuboT (2022) Lecanemab in early Alzheimer’s disease. N Engl J Med388, 9–21.
7.
ChuLW (2012) Alzheimer’s disease: Early diagnosis and treatment. Hong Kong Med J18, 228–237.
8.
Blanco-SilventeL, CastellsX, SaezM, BarcelóMA, Garre-OlmoJ, Vilalta-FranchJ, CapellàD (2017) Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: A meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol20, 519–528.
9.
HsiehYC, GuoC, YalamanchiliHK, AbrehaM, Al-OuranR, LiY, DammerEB, LahJJ, LeveyAI, BennettDA, De JagerPL, SeyfriedNT, LiuZ, ShulmanJM (2019) Tau-mediated disruption of the spliceosome triggers cryptic RNA splicing and neurodegeneration in Alzheimer’s disease. Cell Rep29, 301–316. e310.
10.
WojtasAM, CarlomagnoY, SensJP, KangSS, JensenTD, KurtiA, BakerKE, BerryTJ, PhillipsVR, CastanedesMC, AwanA, DeTureM, De CastroCHF, LibreroAL, YueM, DaughrityL, Jansen-WestKR, CookCN, DicksonDW, PetrucelliL, FryerJD (2020) Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation. Acta Neuropathol Commun8, 210.
11.
Yuste-ChecaP, TrinkausVA, Riera-TurI, ImamogluR, SchallerTF, WangH, DudanovaI, HippMS, BracherA, HartlFU (2021) The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model. Nat Commun12, 4863.
HuentelmanMJ, StephanDA, TalboomJ, CorneveauxJJ, ReimanDM, GerberJD, BarnesCA, AlexanderGE, ReimanEM, Bimonte-NelsonHA (2009) Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci123, 218–223.
14.
PapassotiropoulosA, FountoulakisM, DunckleyT, StephanDA, ReimanEM (2006) Genetics, transcriptomics, and proteomics of Alzheimer’s disease. J Clin Psychiatry67, 652–670.
15.
CouchBA, DeMarcoGJ, GourleySL, KoleskeAJ (2010) Increased dendrite branching in AbetaPP/PS1 mice and elongation of dendrite arbors by fasudil administration. J Alzheimers Dis20, 1003–1008.
16.
SunL, LiuG, SongF, ShiN, LiuF, LiS, LiP, ZhangW, JiangX, ZhangY, SunL, ChenX, ShiY (2020) Combination of four clinical indicators predicts the severe/critical symptom of patients infected COVID-19. J Clin Virol128, 104431.
17.
HamanoT, YenSH, GendronT, KoLW, KuriyamaM (2012) Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging33, 2306–2320.
18.
HamanoT, EnomotoS, ShirafujiN, IkawaM, YamamuraO, YenSH, NakamotoY (2021) Autophagy and tau protein. Int J Mol Sci22, 7475.
19.
LeeHK, Velazquez SanchezC, ChenM, MorinPJ, WellsJM, HanlonEB, XiaW (2016) Three dimensional human neuro-spheroid model of Alzheimer’s disease based on differentiated induced pluripotent stem cells. PLoS One11, e0163072.
20.
LeeHK, MorinP, XiaW (2016) Peripheral blood mononuclear cell-converted induced pluripotent stem cells (iPSCs) from an early onset Alzheimer’s patient. Stem Cell Res16, 213–215.
21.
PaşcaAM, SloanSA, ClarkeLE, TianY, MakinsonCD, HuberN, KimCH, ParkJY, O’RourkeNA, NguyenKD, SmithSJ, HuguenardJR, GeschwindDH, BarresBA, PaşcaSP (2015) Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods12, 671–678.
22.
StathasS, AlvarezVE, XiaW, NicksR, MengG, DaleyS, PothastM, ShahA, KelleyH, EsnaultC, McCormackR, DixonE, FishbeinL, CherryJD, HuberBR, TripodisY, AloscoML, MezJ, McKeeAC, SteinTD (2022) Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer’s disease. Alzheimers Dement18, 1511–1522.
23.
ChenM, LeeHK, MooL, HanlonE, SteinT, XiaW (2018) Common proteomic profiles of induced pluripotent stem cell-derived three-dimensional neurons and brain tissue from Alzheimer patients. J Proteomics182, 21–33.
24.
ChenM, XiaW (2020) Proteomic profiling of plasma and brain tissue from Alzheimer’s disease patients reveals candidate network of plasma biomarkers. J Alzheimers Dis76, 349–368.
25.
KarchCM, CruchagaC, GoateAM (2014) Alzheimer’s disease genetics: From the bench to the clinic. Neuron83, 11–26.
LidströmAM, BogdanovicN, HesseC, VolkmanI, DavidssonP, BlennowK (1998) Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp Neurol154, 511–521.
31.
ProkopenkoD, MorganSL, MullinK, HofmannO, ChapmanB, KirchnerR, AmberkarS, WohlersI, LangeC, HideW, BertramL, TanziRE (2021) Whole-genome sequencing reveals new Alzheimer’s disease-associated rare variants in loci related to synaptic function and neuronal development. Alzheimers Dement17, 1509–1527.
YamazakiY, ShinoharaM, ShinoharaM, YamazakiA, MurrayME, LiesingerAM, HeckmanMG, LesserER, ParisiJE, PetersenRC, DicksonDW, KanekiyoT, BuG (2019) Selective loss of cortical endothelial tight junction proteins during Alzheimer’s disease progression. Brain142, 1077–1092.
37.
LiuG, JiangY, WangP, FengR, JiangN, ChenX, SongH, ChenZ (2012) Cell adhesion molecules contribute to Alzheimer’s disease: Multiple pathway analyses of two genome-wide association studies. J Neurochem120, 190–198.
38.
BaoX, LiuG, JiangY, JiangQ, LiaoM, FengR, ZhangL, MaG, ZhangS, ChenZ, ZhaoB, WangR, LiK, LiuG (2015) Cell adhesion molecule pathway genes are regulated by cis-regulatory SNPs and show significantly altered expression in Alzheimer’s disease brains. Neurobiol Aging36, .2904.e2901–2907.
39.
GardnerAM, VaillancourtRR, JohnsonGL (1993) Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem268, 17896–17901.
40.
WangS, ZhangC, ShengX, ZhangX, WangB, ZhangG (2014) Peripheral expression of MAPK pathways in Alzheimer’s and Parkinson’s diseases. J Clin Neurosci21, 810–814.
41.
KepchiaD, HuangL, DarguschR, RissmanRA, ShokhirevMN, FischerW, SchubertD (2020) Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain. Alzheimers Res Ther12, 75.
42.
CashAD, AlievG, SiedlakSL, NunomuraA, FujiokaH, ZhuX, RainaAK, VintersHV, TabatonM, JohnsonAB, Paula-BarbosaM, AvílaJ, JonesPK, CastellaniRJ, SmithMA, PerryG (2003) Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation. Am J Pathol162, 1623–1627.
43.
JeanDC, BaasPW (2013) It cuts two ways: Microtubule loss during Alzheimer disease. EMBO J32, 2900–2902.
44.
YangX, MaZ, LianP, XuY, CaoX (2023) Common mechanisms underlying axonal transport deficits in neurodegenerative diseases: A mini review. Front Mol Neurosci16, 1172197.
45.
ZempelH, LuedtkeJ, KumarY, BiernatJ, DawsonH, MandelkowE, MandelkowEM (2013) Amyloid-β oligomers induce synaptic damage via tau-dependent microtubule severing by TTLL6 and spastin. EMBO J32, 2920–2937.
46.
GibsonCL, SrivastavaK, SpriggN, BathPM, BayraktutanU (2014) Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions. J Neurochem129, 816–826.
47.
LuissintAC, ArtusC, GlacialF, GaneshamoorthyK, CouraudPO (2012) Tight junctions at the blood brain barrier: Physiological architecture and disease-associated dysregulation. Fluids Barriers CNS9, 23.
48.
RudrabhatlaP, JaffeH, PantHC (2011) Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): Phosphoproteomics of Alzheimer’s NFTs. FASEB J25, 3896–3905.
49.
RudrabhatlaP, GrantP, JaffeH, StrongMJ, PantHC (2010) Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer’s disease by iTRAQ. FASEB J24, 4396–4407.
50.
PerrotR, EyerJ (2009) Neuronal intermediate filaments and neurodegenerative disorders. Brain Res Bull80, 282–295.
51.
DidonnaA, OpalP (2019) The role of neurofilament aggregation in neurodegeneration: Lessons from rare inherited neurological disorders. Mol Neurodegener14, 19.
52.
AmanoM, NakayamaM, KaibuchiK (2010) Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken)67, 545–554.
53.
Zanin-ZhorovA, WeissJM, NyuydzefeMS, ChenW, ScherJU, MoR, DepoilD, RaoN, LiuB, WeiJ, LucasS, KoslowM, RocheM, SchuellerO, WeissS, PoyurovskyMV, TonraJ, HippenKL, DustinML, BlazarBR, LiuCJ, WaksalSD (2014) Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A111, 16814–16819.
54.
ChenF, LiuZ, PengW, GaoZ, OuyangH, YanT, DingS, CaiZ, ZhaoB, MaoL, CaoZ (2018) Activation of EphA4 induced by EphrinA1 exacerbates disruption of the blood-brain barrier following cerebral ischemia-reperfusion via the Rho/ROCK signaling pathway. Exp Ther Med16, 2651–2658.
55.
ZhaoZ, GongS, WangS, MaC (2015) Effect and mechanism of evodiamine against ethanol-induced gastric ulcer in mice by suppressing Rho/NF-κB pathway. Int Immunopharmacol28, 588–595.
56.
LiL, LouX, ZhangK, YuF, ZhaoY, JiangP (2020) Hydrochloride fasudil attenuates brain injury in ICH rats. Transl Neurosci11, 75–86.
LongHZ, ChengY, ZhouZW, LuoHY, WenDD, GaoLC (2021) PI3K/AKT signal pathway: A target of natural products in the prevention and treatment of Alzheimer’s disease and Parkinson’s disease. Front Pharmacol12, 648636.
59.
RazaniE, Pourbagheri-SigaroodiA, Safaroghli-AzarA, ZoghiA, Shanaki-BavarsadM, BashashD (2021) The PI3K/Akt signaling axis in Alzheimer’s disease: A valuable target to stimulate or suppress?Cell Stress Chaperones26, 871–887.
60.
KumarB H, PrasadaK S, PaiSR (2021) Identification of Akt activators for the treatment of Alzheimer’s disease: An In-silico approach. Alzheimers Dement17, e058494.
61.
LeeSJ, ChungYH, JooKM, LimHC, JeonGS, KimD, LeeWB, KimYS, ChaCI (2006) Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats. Neurosci Lett409, 134–139.
PhielCJ, WilsonCA, LeeVM, KleinPS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature423, 435–439.
64.
JacksonGR, Wiedau-PazosM, SangTK, WagleN, BrownCA, MassachiS, GeschwindDH (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron34, 509–519.
65.
LucasJJ, HernándezF, Gómez-RamosP, MoránMA, HenR, AvilaJ (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO20, 27–39.
66.
HernándezF, BorrellJ, GuazaC, AvilaJ, LucasJJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem83, 1529–1533.
67.
ChoJH, JohnsonGV (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem88, 349–358.
68.
DajaniR, FraserE, RoeSM, YeoM, GoodVM, ThompsonV, DaleTC, PearlLH (2003) Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J22, 494–501.
69.
FrameS, CohenP, BiondiRM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell7, 1321–1327.
PalomerE, BuechlerJ, SalinasPC (2019) Wnt signaling deregulation in the aging and Alzheimer’s brain. Front Cell Neurosci13, 227.
72.
PeiY, BrunSN, MarkantSL, LentoW, GibsonP, TaketoMM, GiovanniniM, GilbertsonRJ, Wechsler-ReyaRJ (2012) WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development139, 1724–1733.
73.
TeoJL, KahnM (2010) The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev62, 1149–1155.
74.
Sanghvi-ShahR, WeberGF (2017) Intermediate filaments at the junction of mechanotransduction, migration, and development. Front Cell Dev Biol5, 81.
75.
SjöqvistM, AntfolkD, Suarez-RodriguezF, SahlgrenC (2021) From structural resilience to cell specification – Intermediate filaments as regulators of cell fate. FASEB J35, e21182.
76.
Tejeda-MuñozN, MorselliM, MoriyamaY, SheladiyaP, PellegriniM, De RobertisEM (2022) Canonical Wnt signaling induces focal adhesion and Integrin beta-1 endocytosis. iScience25, 104123.
77.
HeCW, LiaoCP, PanCL (2018) Wnt signalling in the development of axon, dendrites and synapses. Open Biol8, 180116.
78.
LaiS-L, ChienAJ, MoonRT (2009) Wnt/Fz signaling and the cytoskeleton: Potential roles in tumorigenesis. Cell Res19, 532–545.
79.
LiH, PengW, JianW, LiY, LiQ, LiW, XuY (2012) ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol11, 65.
80.
BreitenlechnerC, GasselM, HidakaH, KinzelV, HuberR, EnghRA, BossemeyerD (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: Structural basis of selectivity. Structure11, 1595–1607.
